Goldman Sachs
CSTL icon

Goldman Sachs’s Castle Biosciences CSTL Stock Holding History

Goldman Sachs’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.55M Buy
358,397
+17,226
+5% +$384K ﹤0.01% 3389
2026
Q1 		$8.38M Buy
341,171
+53,936
+19% +$1.77M ﹤0.01% 3208
2025
Q4 		$11.2M Sell
287,235
-57,864
-17% -$1.87M ﹤0.01% 2993
2025
Q3 		$7.86M Buy
345,099
+71,656
+26% +$1.46M ﹤0.01% 3208
2025
Q2 		$5.58M Buy
273,443
+98,118
+56% +$1.82M ﹤0.01% 3310
2025
Q1 		$3.51M Sell
175,325
-257,425
-59% -$6.37M ﹤0.01% 3691
2024
Q4 		$11.5M Buy
432,750
+189,950
+78% +$5.79M ﹤0.01% 2654
2024
Q3 		$6.92M Buy
242,800
+25,663
+12% +$653K ﹤0.01% 3066
2024
Q2 		$4.73M Buy
217,137
+92,465
+74% +$2.06M ﹤0.01% 3203
2024
Q1 		$2.76M Buy
124,672
+44,283
+55% +$963K ﹤0.01% 3609
2023
Q4 		$1.73M Sell
80,389
-71,362
-47% -$1.26M ﹤0.01% 4031
2023
Q3 		$2.56M Buy
151,751
+70,030
+86% +$1.22M ﹤0.01% 3570
2023
Q2 		$1.12M Sell
81,721
-56,193
-41% -$1.14M ﹤0.01% 4272
2023
Q1 		$3.13M Sell
137,914
-108,942
-44% -$2.66M ﹤0.01% 3487
2022
Q4 		$5.81M Buy
246,856
+64,184
+35% +$1.49M ﹤0.01% 3036
2022
Q3 		$4.76M Buy
182,672
+62,987
+53% +$1.77M ﹤0.01% 3174
2022
Q2 		$2.63M Buy
119,685
+56,463
+89% +$1.31M ﹤0.01% 3807
2022
Q1 		$2.84M Sell
63,222
-8,186
-11% -$338K ﹤0.01% 3921
2021
Q4 		$3.06M Sell
71,408
-156,106
-69% -$8.16M ﹤0.01% 3864
2021
Q3 		$15.1M Sell
227,514
-107,101
-32% -$7.54M ﹤0.01% 2323
2021
Q2 		$24.5M Sell
334,615
-69,519
-17% -$4.59M 0.01% 1866
2021
Q1 		$27.7M Buy
404,134
+41,869
+12% +$3.15M 0.01% 1658
2020
Q4 		$24.3M Sell
362,265
-52,651
-13% -$2.85M 0.01% 1697
2020
Q3 		$21.3M Buy
414,916
+114,289
+38% +$5.08M 0.01% 1695
2020
Q2 		$11.3M Sell
300,627
-12,362
-4% -$422K ﹤0.01% 2164
2020
Q1 		$9.33M Buy
312,989
+8,800
+3% +$266K ﹤0.01% 2134
2019
Q4 		$10.5M Buy
304,189
+2,467
+0.8% +$60.3K ﹤0.01% 2399
2019
Q3 		$5.46M Buy
+301,722
New +$6.69M ﹤0.01% 2798

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's CSTL Position: Q2 2026 in Review

Goldman Sachs increased its Castle Biosciences (CSTL) stake by 5% in Q2 2026, buying an estimated $384K and bringing the position to 358,397 shares worth $8.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3389.

Goldman Sachs first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $27.7M in Q1 2021. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Goldman Sachs held 358,397 shares of Castle Biosciences worth $8.55M as of Q2 2026.
  • Goldman Sachs bought 17,226 Castle Biosciences shares in Q2 2026, an estimated $384K.
  • Castle Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3389 holding.
  • Goldman Sachs first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Goldman Sachs's Castle Biosciences position peaked at $27.7M in Q1 2021.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.